Product Description
Mechanisms of Action: H1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Australia | Bangladesh | Belgium | Brazil | Chile | Cyprus | Dominican Republic | Egypt | Estonia | France | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Lithuania | Malaysia | Malta | Morocco | New Zealand | Pakistan | Peru | Portugal | Singapore | Slovakia | South Africa | Spain | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|